GlassScriptPhysician profile
Julio Menocal
NPI 1164492401
$4,523.15
in general payments reported to CMS, 2019-2025
47 companies · $734 in 2025
The $734 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $921 · 2020: $596 · 2021: $199 · 2022: $496 · 2023: $619 · 2024: $958 · 2025: $734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,311.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $704.83 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $549.27 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $466.93 | 2021-2025 | |
| Pfizer INC. | $332.49 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.98 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $201.19 | 2019-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Supernus Pharmaceuticals, INC. | $198.06 | 2019-2022 | |
| Lilly USA, LLC | $196.71 | 2019-2025 | Jardiance, Baqsimi, Lyumjev |
| Mylan Specialty L.P. | $188.36 | 2023-2024 | Yupelri, Yupelri |
| Merck Sharp & Dohme LLC | $174.67 | 2019-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Allergan, INC. | $109.55 | 2019-2020 | |
| Amgen INC. | $104.51 | 2019-2025 | Otezla, Repatha, Repatha |
| Boston Scientific Corporation | $79.27 | 2022 | |
| Amneal Pharmaceuticals LLC | $57.13 | 2020-2025 | Unithroid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.94 | 2019-2025 | Xifaxan |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julio Menocal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.